This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
One critical aspect is the recent approval of KarXT for schizophrenia, which, although positive, was anticipated and thus unlikely to significantly affect the stock’s value. The drug’s labeling was ...
Some results have been hidden because they may be inaccessible to you